HuGE Literature Finder
Records 1-30
|
PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy.
Breast cancer research and treatment 2019 Jul . Jacot William, Dalenc Florence, Lopez-Crapez Evelyne, Chaltiel Leonor, Durigova Anna, Gros Nathalie, Lozano Nicolas, Lacaze Jean-Louis, Pouderoux Stéphane, Gladieff Laurence, Romieu Gilles, Roché Henri, Filleron Thomas, Lamy Pierre-Je |
|
Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
Journal of cancer research and clinical oncology 2019 Feb . Chen Xinyi, Guo Yonghai, Ouyang Tao, Li Jinfeng, Wang Tianfeng, Fan Zhaoqing, Fan Tie, Lin Benyao, Xu Ye, Xie Yunt |
|
Genomic alterations associated with HER2+?breast cancer risk and clinical outcome in response to trastuzumab.
Molecular biology reports 2019 Feb 46 (1): 823-831. Singla Heena, Kaur Raman Preet, Shafi Gowhar, Vashistha Rajesh, Banipal Raja Paramjeet Singh, Kumar Vinod, Munshi Anja |
|
Molecular Alterations and Poziotinib Efficacy, a pan-HER inhibitor, in Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancers: Combined Exploratory Biomarker Analysis from a Phase II Clinical Trial of Poziotinib for Refractory HER2-positive Breast Cancer Patients.
International journal of cancer 2019 Feb . Kim Ji-Yeon, Lee Eunjin, Park Kyunghee, Jung Hae Hyun, Park Woong-Yang, Lee Kyung-Hun, Sohn Joohyuk, Lee Keun Seok, Jung Kyung Hae, Kim Jee Hyun, Lee Ki Hyeong, Im Seock-Ah, Park Yeon H |
|
Molecular Insights into the Classification of Luminal Breast Cancers: The Genomic Heterogeneity of Progesterone-Negative Tumors.
International journal of molecular sciences 2019 Jan 20 (3): . Lopez Gianluca, Costanza Jole, Colleoni Matteo, Fontana Laura, Ferrero Stefano, Miozzo Monica, Fusco Nico |
|
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
Breast cancer research : BCR 2019 03 21 (1): 39. Chia Stephen K L, Martin Miguel, Holmes Frankie A, Ejlertsen Bent, Delaloge Suzette, Moy Beverly, Iwata Hiroji, von Minckwitz Gunter, Mansi Janine, Barrios Carlos H, Gnant Michael, Tomaševic Zorica, Denduluri Neelima, Šeparovic Robert, Kim Sung-Bae, Jakobsen Erik Hugger, Harvey Vernon, Robert Nicholas, Smith John, Harker Graydon, Zhang Bo, Eli Lisa D, Ye Yining, Lalani Alshad S, Buyse Marc, Chan Arle |
|
Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609).
Journal of hematology & oncology 2018 Oct 11 (1): 124. Liang Xu, Briaux Adrien, Becette Véronique, Benoist Camille, Boulai Anais, Chemlali Walid, Schnitzler Anne, Baulande Sylvain, Rivera Sofia, Mouret-Reynier Marie-Ange, Bouvet Laurence Venat, De La Motte Rouge Thibaut, Lemonnier Jérôme, Lerebours Florence, Callens Céli |
|
The prognostic effects of somatic mutations in ER-positive breast cancer.
Nature communications 2018 Sep 9 (1): 3476. Griffith Obi L, Spies Nicholas C, Anurag Meenakshi, Griffith Malachi, Luo Jingqin, Tu Dongsheng, Yeo Belinda, Kunisaki Jason, Miller Christopher A, Krysiak Kilannin, Hundal Jasreet, Ainscough Benjamin J, Skidmore Zachary L, Campbell Katie, Kumar Runjun, Fronick Catrina, Cook Lisa, Snider Jacqueline E, Davies Sherri, Kavuri Shyam M, Chang Eric C, Magrini Vincent, Larson David E, Fulton Robert S, Liu Shuzhen, Leung Samuel, Voduc David, Bose Ron, Dowsett Mitch, Wilson Richard K, Nielsen Torsten O, Mardis Elaine R, Ellis Matthew |
|
Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
Breast cancer research : BCR 2018 Aug 20 (1): 88. Liang Xu, Vacher Sophie, Boulai Anais, Bernard Virginie, Baulande Sylvain, Bohec Mylene, Bièche Ivan, Lerebours Florence, Callens Céli |
|
LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.
Breast cancer research and treatment 2018 Jun . Van Swearingen Amanda E D, Siegel Marni B, Deal Allison M, Sambade Maria J, Hoyle Alan, Hayes D Neil, Jo Heejoon, Little Paul, Dees Elizabeth Claire, Muss Hyman, Jolly Trevor, Zagar Timothy M, Patel Nirali, Miller C Ryan, Parker Joel S, Smith J Keith, Fisher Julie, Shah Nikita, Nabell Lisle, Nanda Rita, Dillon Patrick, Abramson Vandana, Carey Lisa A, Anders Carey |
|
A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP.
Breast (Edinburgh, Scotland) 2018 Apr 40 67-75. Takano Toshimi, Tsurutani Junji, Takahashi Masato, Yamanaka Takeharu, Sakai Kazuko, Ito Yoshinori, Fukuoka Junya, Kimura Hideharu, Kawabata Hidetaka, Tamura Kenji, Matsumoto Koji, Aogi Kenjiro, Sato Kazuhiko, Nishio Kazuto, Nakagawa Kazuhiko, Saeki Toshia |
|
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
Nature communications 2018 Apr 9 (1): 1357. Chen Li, Yang Liu, Yao Ling, Kuang Xia-Ying, Zuo Wen-Jia, Li Shan, Qiao Feng, Liu Yi-Rong, Cao Zhi-Gang, Zhou Shu-Ling, Zhou Xiao-Yan, Yang Wen-Tao, Shi Jin-Xiu, Huang Wei, Hu Xin, Shao Zhi-Mi |
|
HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer.
Breast cancer (Tokyo, Japan) 2018 Apr . Sakai Hitomi, Tsurutani Junji, Iwasa Tsutomu, Komoike Yoshifumi, Sakai Kazuko, Nishio Kazuto, Nakagawa Kazuhi |
|
Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 Apr 36 (10): 981-990. Zardavas Dimitrios, Te Marvelde Luc, Milne Roger L, Fumagalli Debora, Fountzilas George, Kotoula Vassiliki, Razis Evangelia, Papaxoinis George, Joensuu Heikki, Moynahan Mary Ellen, Hennessy Bryan T, Bieche Ivan, Saal Lao H, Stal Olle, Iacopetta Barry, Jensen Jeanette Dupont, O'Toole Sandra, Lopez-Knowles Elena, Barbaraeschi Mattia, Noguchi Shinzaburo, Azim Hatem A, Lerma Enrique, Bachelot Thomas, Wang Qing, Perez-Tenorio Gizeh, Can de Velde Cornelis J H, Rea Daniel W, Sabine Vicky, Bartlett John M S, Sotiriou Christos, Michiels Stefan, Loi Shere |
|
A simple and robust real-time qPCR method for the detection of PIK3CA mutations.
Scientific reports 2018 Mar 8 (1): 4290. Alvarez-Garcia Virginia, Bartos Clare, Keraite Ieva, Trivedi Urmi, Brennan Paul M, Kersaudy-Kerhoas Maïwenn, Gharbi Karim, Oikonomidou Olga, Leslie Nicholas |
|
An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes.
British journal of cancer 2018 Mar . Gy?rffy Balázs, Pongor L?rinc, Bottai Giulia, Li Xiaotong, Budczies Jan, Szabó András, Hatzis Christos, Pusztai Lajos, Santarpia Libe |
|
PIK3CA mutations and their response to neoadjuvant treatment in early breast cancer: A systematic review and meta-analysis.
Thoracic cancer 2018 Mar . Fan Hongwei, Li Chao, Xiang Qian, Xu Ling, Zhang Zhuo, Liu Qianxin, Zhang Tonttong, Zhou Ying, Zhao Xia, Cui Yim |
|
Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients.
Cancer research and treatment : official journal of Korean Cancer Association 2018 Mar . Deng Ling, Zhu Xuehua, Sun Yun, Wang Jiemin, Zhong Xiaorong, Li Jiayuan, Hu Min, Zheng Ho |
|
Solid Papillary Breast Carcinomas Resembling the Tall Cell Variant of Papillary Thyroid Neoplasms (Solid Papillary Carcinomas with Reverse Polarity) Harbor Recurrent Mutations Affecting IDH2 and PIK3CA: A Validation Cohort.
Histopathology 2018 Mar . Lozada John R, Basili Thais, Pareja Fresia, Alemar Barbara, Paula Arnaud C, Gularte-Merida Rodrigo, Giri Dilip D, Querzoli Patrizia, Cserni Gabor, Rakha Emad A, Foschini Maria Pia, Reis-Filho Jorge S, Brogi Edi, Weigelt Britta, Geyer Felipe |
|
Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer.
Molecular cancer 2018 Feb 17 (1): 67. Takeshita Takashi, Yamamoto Yutaka, Yamamoto-Ibusuki Mutsuko, Tomiguchi Mai, Sueta Aiko, Murakami Keiichi, Iwase Hirota |
|
Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients.
PloS one 2018 13 (9): e0203495. Li Guoli, Guo Xinwu, Chen Ming, Tang Lili, Jiang Hui, Day Julia X, Xie Yueliang, Peng Limin, Xu Xunxun, Li Jinliang, Wang Shouman, Xiao Zhi, Dai Lizhong, Wang J |
|
Genetic alterations in sporadic triple negative breast cancer.
Breast (Edinburgh, Scotland) 2017 Dec 38 30-38. Pop Laura-Ancuta, Cojocneanu-Petric Roxana-Maria, Pileczki Valentina, Morar-Bolba Gabriela, Irimie Alexandru, Lazar Vladimir, Lombardo Claudio, Paradiso Angelo, Berindan-Neagoe Ioa |
|
Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2017 Sep . Lavigne Marion, Menet Emmanuelle, Tille Jean-Christophe, Lae Marick, Fuhrmann Laetitia, Bonneau Claire, Deniziaut Gabrielle, Melaabi Samia, Ng Charlotte C K, Marchiò Caterina, Rouzier Roman, Bièche Ivan, Vincent-Salomon An |
|
Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol.
Annals of oncology : official journal of the European Society for Medical Oncology 2017 Sep . Bernichon E, Vallard A, Wang Q, Attignon V, Pissaloux D, Bachelot T, Heudel P E, Ray-Coquard I, Bonnet E, de la Fouchardière A, Faure C, Chopin N, Beurrier F, Racadot S, Sunyach M P, Rancoule C, Perol D, Corset V, Agrapart V, Tinquaut F, Blay J Y, Magné N, Trédan |
|
First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Aug JCO2017733246. Goetz Matthew P, Suman Vera J, Reid Joel M, Northfelt Don W, Mahr Michael A, Ralya Andrew T, Kuffel Mary, Buhrow Sarah A, Safgren Stephanie L, McGovern Renee M, Black John, Dockter Travis, Haddad Tufia, Erlichman Charles, Adjei Alex A, Visscher Dan, Chalmers Zachary R, Frampton Garrett, Kipp Benjamin R, Liu Minetta C, Hawse John R, Doroshow James H, Collins Jerry M, Streicher Howard, Ames Matthew M, Ingle James |
|
Association between the Prevalence of Somatic Mutations in PIK3CA Gene in Tumors and Clinical and Morphological Characteristics of Breast Cancer Patients.
Bulletin of experimental biology and medicine 2017 Jun 163 (2): 250-254. Filipenko M L, Os'kina N A, Oskorbin I A, Mishukova O V, Ovchinnikova L K, Gershtein E S, Kushlinskii N |
|
Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.
Oncology 2017 May 93 (1): . Nishimura Reiki, Toh Uhi, Tanaka Maki, Saimura Michiyo, Okumura Yasuhiro, Saito Tsuyoshi, Tanaka Toshihiro, Teraoka Megumi, Shimada Kazuo, Katayama Kazuhisa, Koga Toshihiro, Kurashita Kaname, Hasegawa Satoshi, Todoroki Hidekazu, Kai Yuichiro, Ohi Yasuyo, Toyoshima Satoshi, Arima Nobuyuki, Mitsuyama Shoshu, Tamura Kaz |
|
Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2017 Mar . Pang Jia-Min B, Savas Peter, Fellowes Andrew P, Mir Arnau Gisela, Kader Tanjina, Vedururu Ravikiran, Hewitt Chelsee, Takano Elena A, Byrne David J, Choong David Yh, Millar Ewan Ka, Lee C Soon, O'Toole Sandra A, Lakhani Sunil R, Cummings Margaret C, Mann G Bruce, Campbell Ian G, Dobrovic Alexander, Loi Sherene, Gorringe Kylie L, Fox Stephen |
|
Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Oncotarget 2017 Mar . Kim Ji-Yeon, Lee Eunjin, Park Kyunghee, Park Woong-Yang, Jung Hae Hyun, Ahn Jin Seok, Im Young-Hyuck, Park Yeon H |
|
The genetic variants in the PTEN/PI3K/AKT pathway predict susceptibility and CE(A)F chemotherapy response to breast cancer and clinical outcomes.
Oncotarget 2017 Mar 8 (12): 20252-20265. Li Xiang, Zhang Ruishan, Liu Zhuangkai, Li Shuang, Xu Ho |
|
Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR(+), HER2(-) advanced breast cancer: results from BOLERO-2.
British journal of cancer 2017 Feb . Moynahan Mary Ellen, Chen David, He Wei, Sung Patricia, Samoila Aliaksandra, You Daoqi, Bhatt Trusha, Patel Parul, Ringeisen Francois, Hortobagyi Gabriel N, Baselga Jose, Chandarlapaty Sar |
|
Identification of frequent somatic mutations in inflammatory breast cancer.
Breast cancer research and treatment 2017 Feb . Matsuda Naoko, Lim Bora, Wang Ying, Krishnamurthy Savitri, Woodward Wendy, Alvarez Ricardo H, Lucci Anthony, Valero Vicente, Reuben James M, Meric-Bernstam Funda, Ueno Naoto |
|
Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.
Oncotarget 2016 Nov . Tury Sandrine, Becette Véronique, Assayag Franck, Vacher Sophie, Benoist Camille, Kamal Maud, Marangoni Elisabetta, Bièche Ivan, Lerebours Florence, Callens Céli |
|
ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast.
Oncotarget 2016 Nov . Ping Zheng, Siegal Gene P, Harada Shuko, Eltoum Isam-Eldin, Youssef Mariam, Shen Tiansheng, He Jianbo, Huang Yingjie, Chen Dongquan, Li Yiping, Bland Kirby I, Chang Helena R, Shen Dej |
|
Clinical outcomes based on multigene profiling in metastatic breast cancer patients.
Oncotarget 2016 Oct . Basho Reva K, Gagliato Debora de Melo, Ueno Naoto T, Wathoo Chetna, Chen Huiqin, Shariati Maryam, Wei Caimiao, Alvarez Ricardo H, Moulder Stacy L, Sahin Aysegul A, Roy-Chowdhuri Sinchita, Chavez-MacGregor Mariana, Litton Jennifer K, Valero Vincent, Luthra Raja, Zeng Jia, Shaw Kenna R, Mendelsohn John, Mills Gordon B, Tripathy Debu, Meric-Bernstam Fun |
|
Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2016 Oct . Geyer Felipe C, Berman Samuel H, Marchiò Caterina, Burke Kathleen A, Guerini-Rocco Elena, Piscuoglio Salvatore, Ng Charlotte Ky, Pareja Fresia, Wen Hannah Y, Hodi Zoltan, Schnitt Stuart J, Rakha Emad A, Ellis Ian O, Norton Larry, Weigelt Britta, Reis-Filho Jorge |
|
Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2016 Oct 27 (10): 1860-6. Fumagalli D, Wilson T R, Salgado R, Lu X, Yu J, O'Brien C, Walter K, Huw L Y, Criscitiello C, Laios I, Jose V, Brown D N, Rothé F, Maetens M, Zardavas D, Savas P, Larsimont D, Piccart-Gebhart M J, Michiels S, Lackner M R, Sotiriou C, Loi |
|
Improving the performance of somatic mutation identification by recovering circulating tumor DNA mutations.
Cancer research 2016 Aug . Fu Yu, Jovelet Cecile, Filleron Thomas, Pedrero Marion, Motté Nelly, Boursin Yannick, Luo Yufei, Massard Christophe, Campone Mario, Levy Christelle, Dieras Veronique, Bachelot Thomas, Garrabey Julie, Soria Jean-Charles, Lacroix Ludovic, Andre Fabrice, Lefebvre Celi |
|
Pictilisib plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2016 Aug . Vuylsteke P, Huizing M, Petrakova K, Roylance R, Laing R, Chan S, Abell F, Gendreau S, Rooney I, Apt D, Zhou J, Singel S, Fehrenbacher |
|
Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
Breast cancer research and treatment 2016 Jul . Kotoula Vassiliki, Karavasilis Vasilios, Zagouri Flora, Kouvatseas George, Giannoulatou Eleni, Gogas Helen, Lakis Sotiris, Pentheroudakis George, Bobos Mattheos, Papadopoulou Kyriaki, Tsolaki Eleftheria, Pectasides Dimitrios, Lazaridis Georgios, Koutras Angelos, Aravantinos Gerasimos, Christodoulou Christos, Papakostas Pavlos, Markopoulos Christos, Zografos George, Papandreou Christos, Fountzilas Geor |
|
LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome.
Molecular oncology 2016 Jul . Ramirez-Ardila Diana E, Ruigrok-Ritstier Kirsten, Helmijr Jean C, Look Maxime P, van Laere Steven, Dirix Luc, Berns Els M J J, Jansen Maurice P H |
|
Metaplastic Breast Cancer: Molecular Typing and Identification of Potential Targeted Therapies at a Single Institution.
Clinical breast cancer 2016 Jul . Edenfield Jessica, Schammel Christine, Collins Justin, Schammel David, Edenfield W Je |
|
Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen.
Oncotarget 2016 May . Jansen Maurice Phm, Martens John Wm, Helmijr Jean Ca, Beaufort Corine M, van Marion Ronald, Krol Niels Mg, Monkhorst Kim, Trapman-Jansen Anita Mac, Meijer-van Gelder Marion E, Weerts Marjolein Ja, Ramirez-Ardila Diana E, Dubbink Hendrikus Jan, Foekens John A, Sleijfer Stefan, Berns Els M |
|
Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
Clinical breast cancer 2016 May . Nakauchi Chiaki, Kagara Naofumi, Shimazu Kenzo, Shimomura Atsushi, Naoi Yasuto, Shimoda Masafumi, Kim Seung Jin, Noguchi Shinzabu |
|
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer - pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2016 May . Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart M, von Minckwitz G, Baselga |
|
Prognostic factors in the myoepithelial-like spindle cell type of metaplastic breast cancer.
Virchows Archiv : an international journal of pathology 2016 May . Leo Fabian, Bartels Stephan, Mägel Lavinia, Framke Theodor, Büsche Guntram, Jonigk Danny, Christgen Matthias, Lehmann Ulrich, Kreipe Ha |
|
Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas.
Neoplasia (New York, N.Y.) 2016 Apr 18 (4): 253-63. Myers Meagan B, Banda Malathi, McKim Karen L, Wang Yiying, Powell Michael J, Parsons Barbara |
|
Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Apr . Dalin Martin G, Desrichard Alexis, Katabi Nora, Makarov Vladimir, Walsh Logan A, Lee Ken-Wing, Wang Qingguo, Armenia Joshua, West Lyndsay, Dogan Snjezana, Wang Lu, Ramaswami Deepa, Ho Alan L, Ganly Ian, Solit David, Berger Michael F, Schultz Nikolaus, Reis-Filho Jorge S, Chan Timothy A, Morris Luc |
|
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Apr . André Fabrice, Hurvitz Sara, Fasolo Angelica, Tseng Ling-Ming, Jerusalem Guy, Wilks Sharon, O'Regan Ruth, Isaacs Claudine, Toi Masakazu, Burris Howard, He Wei, Robinson Douglas, Riester Markus, Taran Tetiana, Chen David, Slamon Denn |
|
Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers.
Experimental and molecular pathology 2016 Apr 100 (3): 421-425. Muller Kristen E, Marotti Jonathan D, de Abreu Francine B, Peterson Jason D, Miller Todd W, Chamberlin Mary D, Tsongalis Gregory J, Tafe Laura |
|
Comparative genomic analysis of primary tumors and metastases in breast cancer.
Oncotarget 2016 Mar . Bertucci François, Finetti Pascal, Guille Arnaud, Adélaïde José, Garnier Séverine, Carbuccia Nadine, Monneur Audrey, Charafe-Jauffret Emmanuelle, Goncalves Anthony, Viens Patrice, Birnbaum Daniel, Chaffanet M |
|
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
The Lancet. Oncology 2016 Mar . Cristofanilli Massimo, Turner Nicholas C, Bondarenko Igor, Ro Jungsil, Im Seock-Ah, Masuda Norikazu, Colleoni Marco, DeMichele Angela, Loi Sherene, Verma Sunil, Iwata Hiroji, Harbeck Nadia, Zhang Ke, Theall Kathy Puyana, Jiang Yuqiu, Bartlett Cynthia Huang, Koehler Maria, Slamon Denn |
|
The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis.
Breast cancer research and treatment 2016 Mar . Engels Charla C, Kiderlen Mandy, Bastiaannet Esther, van Eijk Ronald, Mooyaart Antien, Smit Vincent T H B M, de Craen Anton J M, Kuppen Peter J K, Kroep Judith R, van de Velde Cornelis J H, Liefers Gerrit J |
|
Genomic Characterization of Primary Invasive Lobular Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Feb . Desmedt Christine, Zoppoli Gabriele, Gundem Gunes, Pruneri Giancarlo, Larsimont Denis, Fornili Marco, Fumagalli Debora, Brown David, Rothé Françoise, Vincent Delphine, Kheddoumi Naima, Rouas Ghizlane, Majjaj Samira, Brohée Sylvain, Van Loo Peter, Maisonneuve Patrick, Salgado Roberto, Van Brussel Thomas, Lambrechts Diether, Bose Ron, Metzger Otto, Galant Christine, Bertucci François, Piccart-Gebhart Martine, Viale Giuseppe, Biganzoli Elia, Campbell Peter J, Sotiriou Christ |
|
Whole exome sequencing of rare aggressive breast cancer histologies.
Breast cancer research and treatment 2016 Feb . Dieci Maria Vittoria, Smutná Veronika, Scott Véronique, Yin Guangliang, Xu Ran, Vielh Philippe, Mathieu Marie-Christine, Vicier Cécile, Laporte Melanie, Drusch Francoise, Guarneri Valentina, Conte Pierfranco, Delaloge Suzette, Lacroix Ludovic, Fromigué Olivia, André Fabrice, Lefebvre Celi |
|
PTEN EXPRESSION AND p4EBP1 IMMUNOREACTIVE SCORE AS PREDICTOR FOR pCR IN HER2 POSITIVE BREAST CANCER.
Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Jan . Loibl Sibylle, Darb-Esfahani Silvia, Huober Jens, Klimowicz Alexander, Furlanetto Jenny, Lederer Bianca, Hartmann Arndt, Eidtmann Holger, Pfitzner Berit M, Fasching Peter A, Tiemann Katharina, Jackisch Christian, Mehta Keyur, von Minckwitz Gunter, Untch Michael, Denkert Carst |
|
Diagnostic Accuracy of PIK3CA Mutation Detection by Circulating Free DNA in Breast Cancer: A Meta-Analysis of Diagnostic Test Accuracy.
PloS one 2016 11 (6): e0158143. Zhou Yidong, Wang Changjun, Zhu Hanjiang, Lin Yan, Pan Bo, Zhang Xiaohui, Huang Xin, Xu Qianqian, Xu Yali, Sun Qia |
|
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.
Nature communications 2016 7 11579. Spoerke Jill M, Gendreau Steven, Walter Kimberly, Qiu Jiaheng, Wilson Timothy R, Savage Heidi, Aimi Junko, Derynck Mika K, Chen Meng, Chan Iris T, Amler Lukas C, Hampton Garret M, Johnston Stephen, Krop Ian, Schmid Peter, Lackner Mark |
|
Reproducibility of Digital PCR Assays for Circulating Tumor DNA Analysis in Advanced Breast Cancer.
PloS one 2016 11 (10): e0165023. Hrebien Sarah, O'Leary Ben, Beaney Matthew, Schiavon Gaia, Fribbens Charlotte, Bhambra Amarjit, Johnson Richard, Garcia-Murillas Isaac, Turner Nichol |
|
Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients.
Breast cancer research and treatment 2015 Dec . Liang Diana H, Ensor Joe E, Liu Zhe-Bin, Patel Asmita, Patel Tejal A, Chang Jenny C, Rodriguez Angel |
|
A phase 1 trial of BKM120 (Buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Nov . Ma Cynthia X, Luo Jingqin, Naughton Michael, Ademuyiwa Foluso O, Suresh Rama, Griffith Malachi, Griffith Obi L, Skidmore Zachary, Spies Nicholas C, Ramu Avinash, Trani Lee, Pluard Timothy, Nagaraj Gayathri, Thomas Shana N, Guo Zhanfang, Hoog Jeremy, Han Jing, Mardis Elaine R, Lockhart A Craig, Ellis Matthew |
|
Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer.
Oncotarget 2015 Oct . Lee Ji Yun, Park Kyunghee, Lim Sung Hee, Kim Hae Su, Yoo Kwai Han, Jung Ki Sun, Song Haa-Na, Hong Mineui, Do In-Gu, Ahn TaeJin, Lee Se Kyung, Bae Soo Youn, Kim Seok Won, Lee Jeong Eon, Nam Seok Jin, Kim Duk-Hwan, Jung Hae Hyun, Kim Ji-Yeon, Ahn Jin Seok, Im Young-Hyuck, Park Yeon H |
|
Somatic mutations in breast and serous ovarian cancer young patients: a systematic review and meta-analysis.
Revista da Associac?a?o Me?dica Brasileira (1992) 2015 Oct 61 (5): 474-83. Encinas Giselly, Maistro Simone, Pasini Fátima Solange, Katayama Maria Lucia Hirata, Brentani Maria Mitzi, Bock Geertruida Hendrika de, Folgueira Maria Aparecida Azevedo Koi |
|
The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis.
Breast cancer research and treatment 2015 Aug 152 (3): 463-76. Ibrahim Ezzeldin M, Kazkaz Ghieth A, Al-Mansour Mubarak M, Al-Foheidi Meteb |
|
Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2015 May . Yuan Hua, Chen Jiuan, Liu Yiqiang, Ouyang Tao, Li Jinfeng, Wang Tianfeng, Fan Zhaoqing, Fan Tie, Lin Benyao, Xie Yunt |
|
The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study.
The Journal of pathology 2015 May . Guerini-Rocco Elena, Hodi Zsolt, Piscuoglio Salvatore, Ng Charlotte Ky, Rakha Emad A, Schultheis Anne M, Marchiò Caterina, da Cruz Paula Arnaud, De Filippo Maria R, Martelotto Luciano G, De Mattos-Arruda Leticia, Edelweiss Marcia, Jungbluth Achim A, Fusco Nicola, Norton Larry, Weigelt Britta, Ellis Ian O, Reis-Filho Jorge |
|
Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer.
Oncotarget 2015 Apr 6 (10): 7597-607. Kim Shinn Young, Jung Seung-Hyun, Kim Min Sung, Baek In-Pyo, Lee Sung Hak, Kim Tae-Min, Chung Yeun-Jun, Lee Sug Hyu |
|
Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients.
Molecular oncology 2015 Apr 9 (4): 749-57. Pestrin Marta, Salvianti Francesca, Galardi Francesca, De Luca Francesca, Turner Natalie, Malorni Luca, Pazzagli Mario, Di Leo Angelo, Pinzani Pame |
|
PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015 Apr 33 (12): 1334-9. Majewski Ian J, Nuciforo Paolo, Mittempergher Lorenza, Bosma Astrid J, Eidtmann Holger, Holmes Eileen, Sotiriou Christos, Fumagalli Debora, Jimenez Jose, Aura Claudia, Prudkin Ludmila, Díaz-Delgado Maria Carmen, de la Peña Lorena, Loi Sherene, Ellis Catherine, Schultz Nikolaus, de Azambuja Evandro, Harbeck Nadia, Piccart-Gebhart Martine, Bernards René, Baselga Jo |
|
PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients.
Breast cancer research and treatment 2015 Mar . Oshiro Chiya, Kagara Naofumi, Naoi Yasuto, Shimoda Masafumi, Shimomura Atsushi, Maruyama Naomi, Shimazu Kenzo, Kim Seung Jin, Noguchi Shinzabu |
|
Comprehensive DNA Methylation and Extensive Mutation Analyses of HER2-Positive Breast Cancer.
Oncology 2015 88 (6): 377-84. Yamaguchi Takeshi, Mukai Hirofumi, Yamashita Satoshi, Fujii Satoshi, Ushijima Toshika |
|
Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
PloS one 2015 10 (3): e0120511. Deng Ling, Chen Jie, Zhong Xiao Rong, Luo Ting, Wang Yan Ping, Huang Hui Fen, Yin Li-Juan, Qiu Yan, Bu Hong, Lv Qing, Zheng Ho |
|
Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.
PloS one 2015 10 (10): e0140293. Papaxoinis George, Kotoula Vassiliki, Alexopoulou Zoi, Kalogeras Konstantine T, Zagouri Flora, Timotheadou Eleni, Gogas Helen, Pentheroudakis George, Christodoulou Christos, Koutras Angelos, Bafaloukos Dimitrios, Aravantinos Gerasimos, Papakostas Pavlos, Charalambous Elpida, Papadopoulou Kyriaki, Varthalitis Ioannis, Efstratiou Ioannis, Zaramboukas Thomas, Patsea Helen, Scopa Chrisoula D, Skondra Maria, Kosmidis Paris, Pectasides Dimitrios, Fountzilas Geor |
|
Study of PIK3CA, BRAF, and KRAS mutations in breast carcinomas among Chinese women in Qinghai.
Genetics and molecular research : GMR 2015 14 (4): 14840-6. Wang Y L, Dai X, Li Y D, Cheng R X, Deng B, Geng X X, Zhang H |
|
Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations.
British journal of cancer 2014 Dec 111 (12): 2351-60. Deb S, Wong S Q, Li J, Do H, Weiss J, Byrne D, Chakrabarti A, Bosma T, , Fellowes A, Dobrovic A, Fox S |
|
PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
Hematology/oncology and stem cell therapy 2014 Dec 7 (4): 142-8. Castaneda Carlos A, Lopez-Ilasaca Marco, Pinto Joseph A, Chirinos-Arias Michelle, Doimi Franco, Neciosup Silvia P, Rojas Katerin I, Vidaurre Tatiana, Balko Justin M, Arteaga Carlos L, Gomez Henry |
|
PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Nov 20 (22): 5823-34. Markou Athina, Farkona Sofia, Schiza Christina, Efstathiou Tonia, Kounelis Sophia, Malamos Nikos, Georgoulias Vassilis, Lianidou E |
|
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Oct 32 (29): 3212-20. Loibl Sibylle, von Minckwitz Gunter, Schneeweiss Andreas, Paepke Stefan, Lehmann Annika, Rezai Mahdi, Zahm Dirk M, Sinn Peter, Khandan Fariba, Eidtmann Holger, Dohnal Karel, Heinrichs Clemens, Huober Jens, Pfitzner Berit, Fasching Peter A, Andre Fabrice, Lindner Judith L, Sotiriou Christos, Dykgers August, Guo Sanxing, Gade Stephan, Nekljudova Valentina, Loi Sherene, Untch Michael, Denkert Carst |
|
Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2014 Oct 25 (10): 1959-65. Rothé F, Laes J-F, Lambrechts D, Smeets D, Vincent D, Maetens M, Fumagalli D, Michiels S, Drisis S, Moerman C, Detiffe J-P, Larsimont D, Awada A, Piccart M, Sotiriou C, Ignatiadis |
|
Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival.
Breast cancer research and treatment 2014 Sep 147 (2): 381-7. Pande Mala, Bondy Melissa L, Do Kim-Anh, Sahin Aysegul A, Ying Jun, Mills Gordon B, Thompson Patricia A, Brewster Abenaa |
|
Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Sep 32 (27): 2951-8. Sabine Vicky S, Crozier Cheryl, Brookes Cassandra L, Drake Camilla, Piper Tammy, van de Velde Cornelis J H, Hasenburg Annette, Kieback Dirk G, Markopoulos Christos, Dirix Luc, Seynaeve Caroline, Rea Daniel W, Bartlett John M |
|
Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.
J Clin Oncol 2014 Sep 32 (27): 2951-8. Sabine Vicky S, Crozier Cheryl, Brookes Cassandra L, Drake Camilla, Piper Tammy, van de Velde Cornelis J H, Hasenburg Annette, Kieback Dirk G, Markopoulos Christos, Dirix Luc, Seynaeve Caroline, Rea Daniel W, Bartlett John M |
|
Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.
Breast cancer research and treatment 2014 Aug 147 (1): 211-9. Arthur L M, Turnbull A K, Renshaw L, Keys J, Thomas J S, Wilson T R, Lackner M R, Sims A H, Dixon J |
|
Association between the lengths of GT dinucleotide repeat in the PIK3CA gene with breast cancer risk.
Medical oncology (Northwood, London, England) 2014 Jul 31 (7): 29. Heshmatpour Najmeh, Hematti Simin, Hejazi Seyyed Hossein, Safari Forousan, Tavassoli Manooche |
|
Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer.
Cancer research 2014 Jul 74 (13): 3399-407. Jiang Yi-Zhou, Yu Ke-Da, Bao Jing, Peng Wen-Ting, Shao Zhi-Mi |
|
Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling.
Breast cancer research and treatment 2014 Jun 145 (2): 389-99. Abramson Vandana G, Cooper Lloyd M, Ballinger Tarah, Sanders Melinda E, Du Liping, Lai Darson, Su Zengliu, Mayer Ingrid, Levy Mia, LaFrance Delecia R, Vnencak-Jones Cindy L, Shyr Yu, Dahlman Kimberly B, Pao William, Arteaga Carlos |
|
A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.
The oncologist 2014 May 19 (5): 453-8. Vasan Neil, Yelensky Roman, Wang Kai, Moulder Stacy, Dzimitrowicz Hannah, Avritscher Rony, Wang Baliang, Wu Yun, Cronin Maureen T, Palmer Gary, Symmans W Fraser, Miller Vincent A, Stephens Philip, Pusztai Laj |
|
Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.
Oncotarget 2014 May 5 (10): 3029-38. Wheler Jennifer J, Moulder Stacy L, Naing Aung, Janku Filip, Piha-Paul Sarina A, Falchook Gerald S, Zinner Ralph, Tsimberidou Apostolia M, Fu Siqing, Hong David S, Atkins Johnique T, Yelensky Roman, Stephens Philip J, Kurzrock Razel |
|
Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2014 May 27 (5): 740-50. Ang Daphne C, Warrick Andrea L, Shilling Amy, Beadling Carol, Corless Christopher L, Troxell Megan |
|
GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival.
Cancer 2014 May 120 (9): 1329-37. Jiang Yi-Zhou, Yu Ke-Da, Zuo Wen-Jia, Peng Wen-Ting, Shao Zhi-Mi |
|
Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms.
Oncotarget 2014 May 5 (9): 2349-54. Wheler Jennifer J, Parker Barbara A, Lee Jack J, Atkins Johnique T, Janku Filip, Tsimberidou Apostolia M, Zinner Ralph, Subbiah Vivek, Fu Siqing, Schwab Richard, Moulder Stacy, Valero Vicente, Schwaederle Maria, Yelensky Roman, Miller Vincent A, Stephens M Philip J, Meric-Bernstam Funda, Kurzrock Razel |
|
Analysis of PIK3CA mutations in breast cancer subtypes.
Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry 2014 Jan 22 (1): 50-6. Arsenic Ruza, Lehmann Annika, Budczies Jan, Koch Ines, Prinzler Judith, Kleine-Tebbe Anke, Schewe Christiane, Loibl Sibylle, Dietel Manfred, Denkert Carst |
|
PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy.
Virchows Archiv : an international journal of pathology 2014 Jan 464 (1): 85-93. Cuorvo Lucia Veronica, Verderio Paolo, Ciniselli Chiara Maura, Girlando Salvatore, Decarli Nicola, Leonardi Elena, Ferro Antonella, Caldara Alessia, Triolo Renza, Eccher Claudio, Cantaloni Chiara, Mauri Francesco, Seckl Michael, Volante Marco, Buttitta Fiamma, Marchetti Antonio, Silvia Quattrone, Galligioni Enzo, Palma Paolo Dalla, Barbareschi Matt |
|
An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer.
PloS one 2014 9 (12): e116054. Sueta Aiko, Yamamoto Yutaka, Yamamoto-Ibusuki Mutsuko, Hayashi Mitsuhiro, Takeshita Takashi, Yamamoto Satoko, Iwase Hirota |
|
Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone.
Breast cancer research : BCR 2014 16 (4): 405. Xu Binghe, Guan Zhongzhen, Shen Zhenzhou, Tong Zhongshen, Jiang Zefei, Yang Junlan, DeSilvio Michelle, Russo Mark, Leigh Meggan, Ellis Catheri |
|
Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
Asian Pacific journal of cancer prevention : APJCP 2014 15 (21): 9327-33. Dirican Ebubekir, Kaya Zehra, Gullu Gokce, Peker Irem, Ozmen Tolga, Gulluoglu Bahadir M, Kaya Handan, Ozer Ayse, Akkiprik Musta |
|
PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing.
PloS one 2014 9 (6): e99306. Bai Xusheng, Zhang Enke, Ye Hua, Nandakumar Vijayalakshmi, Wang Zhuo, Chen Lihong, Tang Chuanning, Li Jianhui, Li Huijin, Zhang Wei, Han Wei, Lou Feng, Zhang Dandan, Sun Hong, Dong Haichao, Zhang Guangchun, Liu Zhiyuan, Dong Zhishou, Guo Baishuai, Yan He, Yan Chaowei, Wang Lu, Su Ziyi, Li Yangyang, Jones Lindsey, Huang Xue F, Chen Si-Yi, Gao Jinglo |
|
PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer.
Neoplasma 2014 61 (4): 461-7. Zhang Y, Liu M, Yang H, Wang J, Liu H, Li X, Li J, Xu J, Li |
|
PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Breast cancer research : BCR 2014 16 (1): R13. Beelen Karin, Opdam Mark, Severson Tesa M, Koornstra Rutger H T, Vincent Andrew D, Wesseling Jelle, Muris Jettie J, Berns Els M J J, Vermorken Jan B, van Diest Paul J, Linn Sabine |
|
Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysis.
Scientific reports 2014 4 6255. Pang Bo, Cheng Shi, Sun Shi-Peng, An Cheng, Liu Zhi-Yuan, Feng Xue, Liu Gui-Ji |
- Page last reviewed:Mar 16, 2019
- Page last updated:Apr 07, 2020
- Content source: